Evidence map›Paper›PMID 41051544›Full record

Trial reportPsychopharmacology2026

The effect of methamphetamine and 3,4-methylenedioxymethamphetamine on peripheral endocannabinoid concentrations: a study in healthy adults.

Ana Deutsch, Connor J Haggarty, Gavin N Petrie, Matthew N Hill, Anya K Bershad, Harriet de Wit, Leah M Mayo

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana DeutschDepartment of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Canada.ORCID http://orcid.org/0000-0002-4871-3056
Connor J HaggartyDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.
Gavin N PetrieDepartment of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Matthew N HillDepartment of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Anya K Bershad- Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA.
Harriet de WitDepartment of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA.
Leah M MayoDepartment of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Canada. leah.mayo@ucalgary.ca.ORCID http://orcid.org/0000-0002-0645-4869

Funding

Determinants of Drug Preference in Humans--Administrative SupplementR01DA002812 · NIDA · UNIVERSITY OF CHICAGO · PI DE WIT, HARRIET · 1985 to 2024
$10.6M
NIDA NIH HHS DA02812NIDA NIH HHS R01 DA002812Parker Psychedelics Research Chair at the University of Calgary Parker Psychedelics Research Chair at the University of Calgary
6 · The paper itself

Abstract

rationaleStimulant drugs such as methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA) can impact neurobiological systems implicated in stress, reward processing, and drug use. Although recent preclinical evidence implicates the endocannabinoid (eCB) system in these processes, little is known about the acute effects of stimulants on eCB levels in humans.

objectivesThe aim of the present study was to investigate the effects of acute administration of the prototypical psychostimulant MA and the psychostimulant-empathogen MDMA on circulating eCB levels in healthy adults.

methodsUsing a within-subject, double-blind design, this study assessed the acute effects of MA (20 mg), MDMA (100 mg), and placebo on plasma eCB levels in healthy human participants (N = 22) during three separate sessions. Blood samples assessing concentrations of the eCBs anandamide (AEA) and 2-Arachidonoylglycerol (2-AG) were collected between 150- and 180-minutes post-drug administration, and subjective measures of drug effects were collected at regular intervals.

resultsMA, but not MDMA, was associated with significantly lower 2-AG plasma concentrations compared to placebo. Neither drug impacted AEA concentrations. However, during the placebo condition, higher AEA concentrations were correlated with disliking the 'drug effects', suggesting a possible relationship between AEA levels and negative expectations of subjective drug effects.

conclusionsThese findings provide novel insights into how stimulant drugs act on the eCB system and may help to develop treatments for SUDs.

Indexed as

Central Nervous System StimulantsEndocannabinoidsMethamphetamineN-Methyl-3,4-methylenedioxyamphetamineAdultArachidonic AcidsDouble-Blind MethodFemaleGlyceridesHumansMalePolyunsaturated AlkamidesYoung AdultanandamideArachidonic AcidsCentral Nervous System StimulantsEndocannabinoidsGlyceridesglyceryl 2-arachidonateMethamphetamineN-Methyl-3,4-methylenedioxyamphetaminePolyunsaturated AlkamidesEndocannabinoidsMDMAMethamphetamineStimulantsSubstance use disorders

Identifiers

PMID41051544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.